Failed IBD trial dents confidence in BMS’ deucravacitinibBristol-Myers Squibb’s hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD) Share XFailed IBD trial dents confidence in BMS’ deucravacitinibhttps://pharmaphorum.com/news/failed-ibd-trial-dents-confidence-in-bms-deucravacitinib/
ICER says Amgen’s tezepelumab ‘likely to be too expensive’Amgen and AstraZeneca haven’t won approval or announced a price for their severe asthma therapy tezepelumab should it Share XICER says Amgen’s tezepelumab ‘likely to be too expensive’https://pharmaphorum.com/news/icer-says-amgens-tezepelumab-likely-to-be-too-expensive/
ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRCAmgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting Share XESMO21: First combo data with Amgen’s Lumakras hit the mark in CRChttps://pharmaphorum.com/news/esmo21-first-combo-data-with-amgens-lumakras-hit-the-mark-in-crc/
NHS fast tracks access to Amgen’s just-approved KRAS cancer drugAmgen’s first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement Share XNHS fast tracks access to Amgen’s just-approved KRAS cancer drughttps://pharmaphorum.com/news/nhs-fast-tracks-access-to-amgens-just-approved-kras-cancer-drug/
Amgen builds case for severe asthma drug tezepelumabAmgen and partner AstraZeneca have said their recently filed severe asthma drug tezepelumab has shown impressive results in Share XAmgen builds case for severe asthma drug tezepelumabhttps://pharmaphorum.com/news/amgen-builds-case-for-severe-asthma-drug-tezepelumab/
AZ, Amgen get speedy FDA review for asthma drug tezepelumabThe FDA has started a priority review of AstraZeneca and Amgen’s severe asthma antibody tezepelumab, setting a date Share XAZ, Amgen get speedy FDA review for asthma drug tezepelumabhttps://pharmaphorum.com/news/az-amgen-get-speedy-fda-review-for-severe-asthma-drug-tezepelumab/
Dermavant raises $200m to ease launch of Otezla rival tapinarofDermavant is in line to make some big payments to GlaxoSmithKline if its topical psoriasis drug tapinarof reaches Share XDermavant raises $200m to ease launch of Otezla rival tapinarofhttps://pharmaphorum.com/news/dermavant-raises-200m-to-ease-launch-of-otezla-rival-tapinarof/
Amgen pays Kyowa $400m upfront for OX40 eczema drugAmgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim Share XAmgen pays Kyowa $400m upfront for OX40 eczema drughttps://pharmaphorum.com/news/amgen-pays-kyowa-400m-upfront-for-ox40-eczema-drug/
Amgen nabs speedy approval for first-ever KRAS drug sotorasibAfter decades of mostly unsuccessful R&D, Amgen has claimed the first ever regulatory approval for a drug that Share XAmgen nabs speedy approval for first-ever KRAS drug sotorasibhttps://pharmaphorum.com/news/amgen-nabs-speedy-approval-for-first-ever-kras-drug-sotorasib/
